Welcome, visitor! [ Login

Dragon Lists on the TSX Under Symbol ‘DDD’


Dragon Pharmaceuticals Inc. is pleased to announce that it has received final approval from the Toronto Stock Exchange (TSX) for listing the Company’s shares on the TSX. The shares will be traded under the symbol DDD commencing today. Dragon’s shares will continue to trade on the NASDAQ OTC BB under the symbol DRUG. Maison Placements Canada, Inc. acted as the sponsor for the Company’s TSX listing.

“This is a tremendous step for us as we seek to raise our corporate profile in the investment community,” said Longbin Liu, CEO of Dragon. “Our listing on the TSX will significantly support our efforts to increase the institutional following of our company.”

The TSX has listed Dragon as a technology company. Dragon has developed a proprietary DNA vector technology platform that can be used to construct a wide range of recombinant, or genetically engineered, human protein cell lines. The cell lines developed with Dragon’s technology are capable of producing, at commercial volumes, premium quality proteins at exceptionally high yields and low per unit production costs.

Dragon has validated its proprietary technology platform with the commercial production of Epoetin Alfa (EPO) at the Company’s GMP-certified manufacturing facility in Nanjing, China. Dragon is one of the world’s largest producers of EPO, and is marketing the product in China, Egypt, India and Peru for use in anemia related to chronic renal failure. The Company has initiated, through its 11 international licensees, regulatory submissions for marketing approval throughout Central and Eastern Europe, Southeast Asia, Latin America and the Middle East. Dragon has completed clinical trials and submitted its application to the Chinese State Drug Administration for use of EPO in surgery-related anemia and is currently conducting Phase II/III clinical trials in chemotherapy-related anemia.

The Company is applying its technology platform to other drugs in its development pipeline, which include slow-release EPO, thrombopoietin, granulocyte-colony stimulating factor, and insulin, as well as to its novel drug discovery candidates.

Legal Dragon Pharma

Shop Dragon Pharma Anabolic Steroids – pharmaceutical company that manufactures steroid gear: Buy Femara.

No Tags

3855 total views, 1 today


  • Dragon Ships EPO Internationally

    Dragon Pharmaceuticals Inc. (NASDAQ OTC: DRUG) today announced that it has filled orders for recombinant erythropoietin (EPO) from Egypt, India and Peru where, in addition to China, the Company’s EPO is approved for use in the treatment of anemia related to chronic renal failure. All dollar amounts are stated in US dollars. “Penetrating new markets […]

  • Dragon Pharmaceutical Inc. Announces 2002 Fourth Quarter and Full Year Results

    Dragon Pharmaceutical Inc. (TSX: DDD; OTC BB: DRUG) today announced results for the three-month and twelve-month periods ending December 31, 2002. 2002 Highlights Generated revenues of $7.36 million, representing significant growth from $3.07 million in 2001. Enhancement of gross margin in 2002 to 86.7% from 81% in 2001. Reported a first ever operating profit of […]

  • Dragon Announces Participation at Biopartnering Europe 2001

    Dragon Pharmaceuticals Inc. (OTC BB – DRUG.OB) is pleased to announce that it has been invited to present at the BioPartnering Europe 2001 conference to be held at the Queen Elizabeth II Conference Centre in London, England from October 14th to 16th, 2001. BioPartnering Europe is the premier European venue for showcasing innovative biopharmaceutical and […]

  • Dragon Launches EPO Into the Brazilian Market

    Dragon Pharmaceuticals Inc. (OTC BB: DRUG; TSX: DDD) today announced that it has shipped an order of recombinant erythropoietin (“EPO? to Itaca Laboratorios Ltda., (“Itaca” of Brazil. Itaca, a distribution partner of the company, has won a 3.1 million Brazilian Real tender for Dragon’s EPO in the Brazilian state of Minas, Gerais, which converts to […]

  • Dragon Signs Licensing Agreement for Korea

    Dragon Pharmaceuticals Inc. (OTCBB – DRUG.OB) today announced that it has entered into a marketing and licensing agreement with Boryung Biopharma Company, Ltd. of Seoul, Korea for the distribution of recombinant Erythropoietin (EPO) in North and South Korea. According to the agreement, Boryung Biopharma will also be responsible for obtaining marketing for EPO from the […]

Dragon Pharma Suppliers

dragon pharma source
american steroids online
real dragon pharma supplier
dragon pharma for sale
dragon pharma legit supplier
buy dragon pharma
dragon pharma store
buy steroids
dragon pharma legit dragon pharma anabolics